Growth of Benign and Malignant Schwannoma Xenografts in Severe Combined Immunodeficiency Mice-Reference-Cited by-同舟云学术

Growth of Benign and Malignant Schwannoma Xenografts in Severe Combined Immunodeficiency Mice

Published:2006-11 Issue:11 Volume:116 Page:2018-2026
ISSN:0023-852X
Container-title:The Laryngoscope
language:en
Short-container-title:The Laryngoscope

Author:

Chang Long-Sheng,Abraham Jacob,Lorenz Mark,Rock Jonathan,Akhmametyeva Elena M.,Mihai Georgeta,Schmalbrock Petra,Chaudhury Abhik R.,Lopez Raul,Yamate Jyoji,John Markus R.,Wickert Hannes,Neff Brian A.,Dodson Edward,Welling D Bradley

Publisher

Wiley

Subject

Otorhinolaryngology

Reference21 articles.

1. The Molecular Biology of Vestibular Schwannomas: Dissecting the Pathogenic Process at the Molecular Level

2. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2

3. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor

4. Histopathology and Growth Pattern of Cystic Acoustic Neuromas

5. Cystic vestibular schwannoma: surgical outcome

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumors of the nervous system and hearing loss: Beyond vestibular schwannomas;Hearing Research;2024-06

2. The genetic landscape and possible therapeutics of neurofibromatosis type 2;Cancer Cell International;2023-05-23

3. WP1066 induces cell death in a schwannomatosis patient–derived schwannoma cell line;Molecular Case Studies;2022-06

4. Novel patient‐derived xenograft and cell line models for therapeutic screening in NF2 ‐associated schwannoma;The Journal of Pathology;2022-04-28

5. Early phase clinical studies of AR ‐42, a histone deacetylase inhibitor, for neurofibromatosis type 2‐associated vestibular schwannomas and meningiomas;Laryngoscope Investigative Otolaryngology;2021-08-20